151 related articles for article (PubMed ID: 32015044)
41. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
42. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Cihlar T; Fuller MD; Mulato AS; Cherrington JM
Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
[TBL] [Abstract][Full Text] [Related]
43. Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient.
Chibo D; Mijch A; Doherty R; Birch C
J Clin Virol; 2002 Aug; 25(2):165-70. PubMed ID: 12367650
[TBL] [Abstract][Full Text] [Related]
44. Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.
Tchesnokov EP; Obikhod A; Schinazi RF; Götte M
J Biol Chem; 2009 Sep; 284(39):26439-46. PubMed ID: 19622750
[TBL] [Abstract][Full Text] [Related]
45. Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively.
Baldanti F; Sarasini A; Silini E; Barbi M; Lazzarin A; Biron KK; Gerna G
Scand J Infect Dis Suppl; 1995; 99():103-4. PubMed ID: 8668930
[TBL] [Abstract][Full Text] [Related]
46. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
Campos AB; Ribeiro J; Boutolleau D; Sousa H
Rev Med Virol; 2016 May; 26(3):161-82. PubMed ID: 26990717
[TBL] [Abstract][Full Text] [Related]
47. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs.
Baldanti F; Lurain N; Gerna G
Hum Immunol; 2004 May; 65(5):403-9. PubMed ID: 15172438
[TBL] [Abstract][Full Text] [Related]
48. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.
Gilbert C; Boivin G
Antimicrob Agents Chemother; 2005 Dec; 49(12):4860-6. PubMed ID: 16304146
[TBL] [Abstract][Full Text] [Related]
49. Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.
Boutolleau D; Canestri A; Burrel S; Wirden M; Seang S; Clavel-Osorio C; Marcelin AG; Katlama C; Agut H
J Clin Virol; 2012 Jun; 54(2):194-6. PubMed ID: 22398036
[TBL] [Abstract][Full Text] [Related]
50. Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance.
Pérez JL
Microbiologia; 1997 Sep; 13(3):343-52. PubMed ID: 9353754
[TBL] [Abstract][Full Text] [Related]
51. Differential resistance to antiviral drugs in an immunocompromised patient with cytomegalovirus encephalitis.
Wada T; Mase S; Shibata F; Shimizu M; Toma T; Yachie A
J Clin Virol; 2010 Nov; 49(3):223-4. PubMed ID: 20801077
[No Abstract] [Full Text] [Related]
52. Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance.
Shi R; Azzi A; Gilbert C; Boivin G; Lin SX
Proteins; 2006 Aug; 64(2):301-7. PubMed ID: 16705640
[TBL] [Abstract][Full Text] [Related]
53. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
[TBL] [Abstract][Full Text] [Related]
54. High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations.
Baradhi KM; Aure RL; El-Amm JM
Transplant Proc; 2018; 50(1):142-144. PubMed ID: 29407298
[TBL] [Abstract][Full Text] [Related]
55. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
[TBL] [Abstract][Full Text] [Related]
56. Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model.
Hantz S; Cotin S; Borst E; Couvreux A; Salmier A; Garrigue I; Merville P; Mengelle C; Attal M; Messerle M; Alain S
Antiviral Res; 2013 Apr; 98(1):130-4. PubMed ID: 23415883
[TBL] [Abstract][Full Text] [Related]
57. [In vitro susceptibility to ganciclovir and foscarnet of cytomegaloviruses].
Otegui M; Rabella N; Labeaga R; Herrero M; Margall R; Muñoz JM; Prats G
Rev Esp Quimioter; 2001 Jun; 14(2):155-64. PubMed ID: 11704769
[TBL] [Abstract][Full Text] [Related]
58. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation.
Shapira MY; Resnick IB; Chou S; Neumann AU; Lurain NS; Stamminger T; Caplan O; Saleh N; Efferth T; Marschall M; Wolf DG
Clin Infect Dis; 2008 May; 46(9):1455-7. PubMed ID: 18419454
[TBL] [Abstract][Full Text] [Related]
59. Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens.
Daikoku T; Saito K; Aihara T; Ikeda M; Takahashi Y; Hosoi H; Nishida T; Takemoto M; Shiraki K
Microbiol Immunol; 2013 May; 57(5):396-9. PubMed ID: 23668613
[TBL] [Abstract][Full Text] [Related]
60. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
Chou S; Satterwhite LE; Ercolani RJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
